Contacts
ASTeCC
Tanya Floyd / (859) 218-6563
A152 ASTeCC Building
Economic Development
Len Heller / (859) 218-6512
A256 ASTeCC Building
Von Allmen Center for Entrepreneurship
Dean Harvey / (859) 257-1930
A107 ASTeCC Building
- About ASTeCC / AgTeCC Campus Incubators
- ASTeCC Faculty Research Programs
- ASTeCC Graduates
- ASTeCC Shared Research and Support Resources
ASTeCC Companies
3H Company LLC
Based on research by Liang Hu / 757.725.1213
Specializes in research and development of clean coal technologies, with emphasis on CO2 capture technologies. Current partners include Nexant Inc., Bechtel Power Corporation, Western Kentucky University and Sask Power.Adaptive Intelligent Systems
Based on reasearch by Yuming Zhang / electrical engineering
Develops cutting edge welding technology including a modified GMAW process that reduces heat input and improves throughput, and a state-of-the-art pipe welding system which allows welders with minimum skills to produce quality welds. Company founded in 2005.
Coldstream Digital
Specializes in intelligent transportation systems, hazmat supply chain security, and electronic manifest and shipment tracking systems for homeland security and the transportation industry. Partners with the Kentucky Transportation Center at UK in the North American Transportation Security Center initiative.
CoPlex Therapeutics
Based on research by Mark Lovell and Bert Lynn / chemistry
R&D to provide neuroprotection from dementia caused by a unique protein complex that accumulates in the central nervous system and begins the cascade effect that leads to dementia including Alzheimer’s. Protein complex discovered at UK. Company founded in 2008.
HiberNetics
Based on research by Peter Oeltgen / medicine
HiberNetics is identifying the clinical potential of opioid peptides, referred to as deltorphins, in treating stroke. Current research indicates that the use of these peptides within minutes to hours after a stroke can provide a dramatic new approach to neuroprotection. HiberNetics has demonstrated that these deltorphins can also reduce cerebral and myocardial ischemic injury and enhance survival following severe hemorrhage.
IP Pharmaceuticals
Based on research by Guangxiang Luo / microbiology, immunology and molecular genetics
Develops novel technologies and reagents for antiviral drug discovery focusing on therapeutics and vaccines to treat infectious diseases caused by viruses such as hepatitis, influenza, West Nile (WNV), Dengue, and respiratory syncytial (RSV) viruses.
Nano-Mite Technologies
Based on research by Patrick Sullivan / SCoBIRC and anatomy & neurobiology
R&D to control obesity using nanotechnology to alter the body’s metabolic rate and increase the cell’s ability to convert sugar to energy. Research could lead to future breakthroughs in the treatment of traumatic central nervous system damage and neurodegenerative disorders. Company founded in 2002.
NanoTech Solutions
Based on research by Vijay Singh / engineering
NanoTech Solutions (NTS) produces high quality nanoporus metal oxide templates that offer a cost effective approach to creating nanoscale products for electronic and biological nanotech devices. These devices include nanowire photovoltaics, sensors, memory devices, filtration and flow membranes, substrates for aligned nanotube array growth, biological assay, cell growth and controlled biochemical reactions. NTS has received a Kentucky seed grant to use in commercializing its nanoporous alumnia technology.
NeoCytex Biopharma
Develops novel therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.
Outrider Technologies
Based on research by John Anthony / chemistry
In the third year of research on next generation semiconductor materials in the plastic electronic industry. Provides research support to electronic companies worldwide.
ParaTechs Corporation
Based on research by Bruce Webb / entomology
Applies advances in insect molecular biology to identify genes and proteins from insect parasites and pathogens that can be used for insect control and natural product development. Also markets novel products that enable discovery and development in biotechnology. Company formed in 2004.
Scout Diagnostics
Based on research by Mark Lovell and Bert Lynn / chemistry
Focused on developing an early diagnostic test for Alzheimer’s disease that identifies certain protein complexes in cerebral spinal fluid that serve as biomarkers to detect Alzheimer’s prior to clinical diagnosis. Company founded in 2006.
Synergetic Technologies
Based on research by
M.P. Menguc / mechanical engineering
Develops scientific instrumentation and software for the accurate characterization (particle shape or agglomerate structure) of nano or sub-micron sized particles. Licensed its particle characterization technology to Horiba Inc., Japan, a major manufacturer of analytical instruments in 2007.
Transposagen Biopharmaceuticals
Produces genetically modified MutaRat™ Knockout Animal Models of human diseases for drug discovery and development. The production of animal models is a $1.2 billion/year market and is expected to grow 12 percent annually through 2010. Company founded in 2003.
Transposagen Creates a Rat Model of the Human Immune System
Vindico NanoBiologyTechnology (coming soon)
Naprogenix
Based on research by John Littleton / molecular pharmacology and plant genomics
Commercialized technology that enables bio-prospecting (screening) of Kentucky native plants and mutant plants for molecules that could lead to plant-based medicines and natural insecticides. Founded in 2002, the company’s current focus is on non-toxic insecticides, CNS-acting drugs and chemotherapeutic agents.
Oraceuticals
Based on research by
Jeff Ebersole / dentistry
Uses the latest biotechnologies to develop drugs that advance oral treatment and improve oral health. Focuses on producing novel bioactive molecules that target chronic oral infections and control inflammation.
Yaupon Therapeutics
Based on research by Peter Crooks and Linda Dwoskin / pharmaceutical sciences
Privately held specialty pharmaceutical company developing therapeutics for cancer and central nervous system diseases. Currently four products in development, with one compound in pivotal studies, one compound in Phase II , a compound for treatment of ADHD in Phase I, and additional compounds that will enter the clinic in 12 months.